Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 52-week study of benralizumab in adults with rare non-asthmatic eosinophilic diseases
MOH_2021-03-09_009818Phase 3Not yet recruiting
- Sponsor
- ד"ר יובל טל
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in eosinophilic bronchitis (EB), eosinophilic cystitis (EC), eosinophilic fasciitis (EF) and 6 more, sponsored by ד"ר יובל טל. Primary endpoint: Responder status at week 24. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic bronchitis (EB)eosinophilic cystitis (EC)eosinophilic fasciitis (EF)Eosinophilic Pneumonia (EP)eosinophilic cellulitis (EC)
Beyond the preview
Go deeper on MOH_2021-03-09_009818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-09_009818.